Open AccessAtopic dermatitis: Tofacitinib, an option for refractory disease
Author(s) -
Berbert Ferreira Sineida,
Berbert Ferreira Rachel,
Scheinberg Morton Aaron
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3325
Subject(s) - tofacitinib , medicine , atopic dermatitis , refractory (planetary science) , dermatology , disease , quality of life (healthcare) , rheumatoid arthritis , physics , nursing , astrobiology
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.